R&D strategy

• Focusing research area : liver/GI diseases (profit volume-up)
• Market-oriented research and development(sales maximization)
• Strengthening R&&D collaboration and strategic alliance (risk hedging)
• Challenging new field for the future(risk taking)

R&D technology

• Drug delivery system : slow-releasing, nanotechnology (improving BA) with venture research instituties (partnership)
• Modernization of Phytomedicine : purification & standardization of extract with academic institutes (collaboration)
• Formulation & Process development for drug quality & stability
• Challenging new field for the future(risk taking)

R&D Projects

Short-term(1~2 years)	Generic drugs	Varsartan, Olmesartan, doxophylline, etc.
Middle-term(3-5 years)	Improved drugs	Liver diseases : PMK-M02GI1(ASH-combination)                          PMK-N01GI1(NASH-chemical) GI diseases : PMK-N01GI2(Chemical) Respiratory diseases : PMK-N02RS1(Natural) Others : PMK-M01RS1(Nano-particle)               PMK-N02GI1(anti-inflammation)               OTC drugs/Medical device and Kit
Long-term(6 years~)	Innovative drugs	Antiaging; PMK-L01(chemical) Alzheimer; PMK-L02 (natural)